Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 200.79

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Torben Noerup Nielsen who wrote (20508)	5/11/1998 8:58:00 PM
From: squetch	Read Replies (3) of 32384

Torben, The numbers I read were 5 to 10 thousands incidences of CTCL in US w/ 500 to 1000 new cases a year. There is currently no approved therapy. I'm NOT at all saying these will compare, but for those who don't think you can make much dough in a small patient population, look at GENZ's Ceradase/Cerezyme sales. GENZ has no competition b/c there are 5,000 patients world wide w/ Gaucher's disease. 96 sales were over 250 million. No competition is why GENZ can charge so much. So again I am not saying LGND will do 250 million. squetch

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next